Stock Events

Stock Events

Soleno Therapeutics 

€30.74
42
+€4.74+18.23% Thursday 13:25

Statistics

Day High
31.08
Day Low
31
52W High
73.1
52W Low
25.52
Volume
-
Avg. Volume
-
Mkt Cap
1.65B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.83
-0.95
-0.08
0.8
Expected EPS
0.656923
Actual EPS
N/A

Financials

10.01%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
324.41MRevenue
32.47MNet Income

Analyst Ratings

$68.90Average Price Target
The highest estimate is 86.50.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6XC.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, directly competing with Soleno's therapeutic areas.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, competing in the same therapeutic area as Soleno.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics operates in the field of genetic disorders, including rare diseases, making it a direct competitor to Soleno Therapeutics.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its advanced therapies, competing in the same niche as Soleno.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, including treatments for rare diseases, overlapping with Soleno's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, targeting genetic and rare diseases, which puts it in competition with Soleno.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing technology, which has applications in treating rare diseases, potentially competing with Soleno's therapeutic approach.

About

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Anish Bhatnagar M.D.
Employees
133
Country
US
ISIN
US8342033094
WKN
000A3DS0P

Listings

XNAS
US
SLNO
F
DE
6XC.F
MI
IT
1SLNO.MI
BOATS
BOATS
SLNO.BOATS

0 Comments

Share your thoughts

FAQ

What is Soleno Therapeutics stock price today?▼
The current price of 6XC.F is €30.74 EUR — it has increased by +18.23% in the past 24 hours. Watch Soleno Therapeutics stock price performance more closely on the chart.
What is Soleno Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Soleno Therapeutics stocks are traded under the ticker 6XC.F.
Is Soleno Therapeutics stock price growing?▼
6XC.F stock has risen by +20.45% compared to the previous week, the month change is a -4% fall, over the last year Soleno Therapeutics has showed a -50.82% decrease.
What is Soleno Therapeutics market cap?▼
Today Soleno Therapeutics has the market capitalization of 1.65B
When is the next Soleno Therapeutics earnings date?▼
Soleno Therapeutics is going to release the next earnings report on May 12, 2026.
What were Soleno Therapeutics earnings last quarter?▼
6XC.F earnings for the last quarter are 0.68 EUR per share, whereas the estimation was 0.6 EUR resulting in a +12.55% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Soleno Therapeutics revenue for the last year?▼
Soleno Therapeutics revenue for the last year amounts to 324.41M EUR.
What is Soleno Therapeutics net income for the last year?▼
6XC.F net income for the last year is 32.47M EUR.
How many employees does Soleno Therapeutics have?▼
As of April 04, 2026, the company has 133 employees.
In which sector is Soleno Therapeutics located?▼
Soleno Therapeutics operates in the Health Care sector.
When did Soleno Therapeutics complete a stock split?▼
The last stock split for Soleno Therapeutics was on August 26, 2022 with a ratio of 1:15.
Where is Soleno Therapeutics headquartered?▼
Soleno Therapeutics is headquartered in Redwood City, US.